|Articles|August 15, 2002
Study promising: Joint venture to target dry AMD treatment
St. Louis, MO-TLC Vision Corp. has made an equity investment in Vascular Sciences Corp. to establish OccuLogix, a 50/50 joint venture to commercialize Vascular Sciences' Rheopheresis blood filtration process for treating age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























